Download Files:

Cabozantinib

SKU T2586-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 62 CAD through 419 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

1 mL * 10 mM (in DMSO)10 mg 100 mg 200 mg 5 mg 50 mg 500 mg

Clear

Products Details

Product Description

– Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T2586

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C28H24FN3O5

Citations

– 1. Chu T H, Ko C Y, Tai P H, et al. Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. Journal of Biological Chemistry. 2022: 102442. 2. Sequera C, Grattarola M, Holczbauer A, et al.MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities.Cell death & disease.2022, 13(11): 1-15. 3. Zaccagnino A, Vynnytska-Myronovska B, Stöckle M, et al.An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.International Journal of Molecular Sciences.2023, 24(6): 5648. 4. Di T, Luo Q, Song J, et al.APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways.International Immunopharmacology.2024, 139: 112615. 5. Haga Y, Ray R, Ray R B.Silmitasertib in Combination With Cabozantinib Impairs Liver Cancer Cell Cycle Progression, Induces Apoptosis, and Delays Tumor Growth in a Preclinical Model.Molecular Carcinogenesis.2024 6. Breitenecker K, Hedrich V, Pupp F, et al.Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.Frontiers in Oncology.2023, 13: 1238883.

References

– Dai J, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res. 2014 Feb 1;20(3):617-30.

CAS Number

– 849217-68-1

Molecular Weight

– C28H24FN3O5

Compound Purity

– 0.9988

SMILES

– C(NC1=CC=C(OC=2C3=C(C=C(OC)C(OC)=C3)N=CC2)C=C1)(=O)C4(C(NC5=CC=C(F)C=C5)=O)CC4

Pathway

– Angiogenesis|||Apoptosis|||Tyrosine Kinase/Adaptors

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.